New hope for rare blau syndrome: tofacitinib under the microscope
NCT ID NCT06688838
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at how well the drug tofacitinib works for people with Blau syndrome, a rare genetic condition that causes inflammation in the joints, eyes, and skin. Researchers will review medical records from 24 participants to see if tofacitinib helps control the disease. The goal is to find better treatment options for those who don't respond to standard therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib
What this could lead to
If successful, this could point toward a more effective treatment option for people with Blau syndrome who do not respond to standard therapies.
What could go wrong
This is a small, early-stage observational study with only 24 participants, so results may not apply to everyone. Tofacitinib may cause side effects like increased infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLAU SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yikai YU
Wuhan, Hubei, 430030, China